Page 1

inventiva PRESS RELEASE Inventiva Reports First - Half of 2021 Financial Information Cash and cash equivalents at € 93.6 m as of June 30 , 2021 Revenues of € 0.2 m in H1 2021 Daix ( France ) , July 28 , 2021 – Inventiva ( Euronext Paris and Nasdaq : IVA ) , a clinical - stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non - alcoholic steatohepatitis ( NASH ) , mucopolysaccharidoses ( MPS ) and other diseases with significant unmet medical need , today reported its cash position as of June 30 , 2021 and its revenues for the first half of 2021¹ . Cash Position As of June 30 , 2021 , Inventiva's cash and cash equivalents stood at € 93.6 million compared to € 107.8 million as of March 31 , 2021 and € 113.02 million as of December 31 , 2020 . Net cash used in operating activities amounted to € 19.8 million in the first half of 2021 compared to € 7.2 million for the same period in 2020. R & D expenses for the first half of 2021 were up 56 % compared to the first half of 2020 , mainly driven by the development of lanifibranor in NASH and costs linked to the preparation for the initiation of NATIV3 , the Company's Phase III clinical trial evaluating lanifibranor in NASH . This amount includes the payment received on June 30 , 2021 of € 8.0 million of Research Tax Credit ( CIR - Crédit Impôt Recherche ) ( € 3.8 million related to complementary filings following the 2020 Conseil d'État judgement covering prior years , and € 4.2 million related to the 2020 Research Tax Credit ) , while the first half of 2020 had been positively impacted by the receipt of a € 4.2 million non - recurrent late payment of the 2018 Research Tax Credit and a € 4.2 million payment in respect of the 2019 Research Tax Credit . Net cash used from investing activities amounted to € 1.2 million in the first half of 2021 compared to 1.0 million for the same period in 2020 . No net cash from financing activities was generated over the first half of 2021 while Inventiva recorded € 24.6 million of net cash from financing activities for the same period in 2020 , notably related to the issuance of € 15 million ( gross proceeds ) of ordinary shares in February 2020 and the entry into a € 10.0 million State- guaranteed loan , with a syndicate of French banks in May 2020 . Over the first semester of 2021 , the Company recorded a positive exchange rate effect on cash and cash equivalent of € 1.2 million . Considering its current R & D and clinical development programs , and excluding additional financial resources , Inventiva's cash runway will allow to fund its operating activities through the third quarter of 2022 . Revenues The Company's revenues for the first half of 2021 amounted to € 0.2 million , as compared to € 0.1 million for the same period in 2020 . 1 Non - audited financial information . 2 The cash position includes cash and cash equivalents as well as short - term deposits which are included in the category " other current assets " in the IFRS statement of financial position as of December 31 , 2020 . 1